Gene Bridges granted Korean Patent for Recombineering Technology
Gene Bridges GmbH announced that it has been granted Korean Patent No. 10-0751587, entitled "Methods and compositions for directed cloning and sub-cloning using homologous recombination" by the Korean Patent Office. The patent broadly covers the major areas of Gene Bridges' RED/ET recombineering technology. This is the same technology that is already covered by issued patents in the USA and EU.
Gary Stevens, CEO of Gene Bridges GmbH, commented: 'Recombineering is the technology of choice in DNA engineering and is used worldwide in industry and academia. In addition to the patents already granted Gene Bridges, this forms a part of the strong intellectual property position Gene Bridges is building worldwide. Korea has an important and growing life sciences sector and we look forward to working with the leading institutes and companies there.'
Red/ET is a method for DNA engineering. According to the company, recombineering with Red/ET allows unlimited cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Autoimmune Reaction Successfully Halted in Early Stage Islet Autoimmunity
Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years

Illuminating the genome - RNA-guided endonuclease - in situ labelling, a new CRISPR/Cas9 based molecular visualisation method

A.R.C.O.- Chemie GmbH - Herdecke, Germany
St. Anna Kinderkrebsforschung - Wien, Austria

Inflammation halts fat-burning
New mathematical theory says small organisms may not form species

Merck Completes Acquisition of Exelead and Plans to Invest More Than € 500 Million in Technology Scale-Up - Company now offers comprehensive end-to-end services across mRNA value chain
Resurrection of 3-billion-year-old antibiotic-resistance proteins
Selvita Signs a Drug Discovery Services Contract With Rottapharm Madaus
Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours
